TY - JOUR
T1 - Conducting an Oral Food Challenge
T2 - An Update to the 2009 Adverse Reactions to Foods Committee Work Group Report
AU - Bird, J. Andrew
AU - Leonard, Stephanie
AU - Groetch, Marion
AU - Assa'ad, Amal
AU - Cianferoni, Antonella
AU - Clark, April
AU - Crain, Maria
AU - Fausnight, Tracy
AU - Fleischer, David
AU - Green, Todd
AU - Greenhawt, Matthew
AU - Herbert, Linda
AU - Lanser, Bruce J.
AU - Mikhail, Irene
AU - Mustafa, Shahzad
AU - Noone, Sally
AU - Parrish, Christopher
AU - Varshney, Pooja
AU - Vlieg-Boerstra, Berber
AU - Young, Michael C.
AU - Sicherer, Scott
AU - Nowak-Wegrzyn, Anna
N1 - Funding Information:
Conflicts of interest: J. A. Bird reports personal fees and nonfinancial support from the American College of Allergy, Asthma and Immunology, Food Allergy Research and Education (FARE); grants from Nestle Health Sciences, National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases, and Genentech; personal fees from Nutricia North America, Pharm-Olam International Ltd, Prota Therapeutics, Allergy Therapeutics, Ltd, AllerGenis, and Abbott Nutrition International; personal fees and other fees from Pfizer Pharmaceuticals; grants, personal fees, and nonfinancial support from Aimmune Therapeutics; and grants and personal fees from DBV Technologies; outside the submitted work. S. Leonard reports other fees from DBV Technologies and Aimmune Therapeutics; grants and personal fees from FARE; and personal fees from LabCorp and Annenberg Center for Health Sciences at Eisenhower, outside the submitted work. A. Assa'ad reports grants from Aimmune, DBV Technologies, Astellas, sanofi-aventis, AbbVie, and NIH, outside the submitted work; and has a patent IL-4 polymorphisms with royalties paid. A. Clark reports personal fees from Nutricia North America, outside the submitted work. M. Crain reports personal fees from Aimmune Therapeutics and DBV Technologies, outside the submitted work. D. Fleischer reports other fees from National Peanut Board, Food Allergy & Anaphylaxis Connection Team (FAACT), FARE Clinical Advisory Board; has received personal fees from UpToDate, Kaleo Pharmaceutical, INSYS Therapeutics, AllerGenis, Nutricia, American College of Allergy, Asthma and Immunology (ACAAI), Medscape, and Abbott; has received grants from Aimmune Therapeutics; and has received grants and personal fees from DBV Technologies, outside the submitted work. T. Green reports other fees from DBV Technologies; and has received grants from Aimmune Therapeutics, outside the submitted work. M. Greenhawt reports personal fees from DBV, Aimmune, Allergy Therapeutics, Aquestive, Allergenis, Aravax, Genentech, Sanofi Genzyme, Monsanto, Thermo Fisher, Canadian Transport Agency, Medscape, Allergy and Asthma Network, Institute for Clinical and Economic Review, Prota, Intrommune, Kaleo, Merck, Galaxo Smith Kline, Before Brands, multiple state medical societies, and ACAAI; other fees from NIAID, Australasian Society of Clinical Immunology and Allergy; has received nonfinancial support from the International FPIES Association, the European Academy of Allergy and Clinical Immunology, Asthma and Allergy Foundation of America, and the National Peanut Board; has received grants from the Agency for Healthcare Research and Quality; and has received nonfinancial support and other fees from the Joint Taskforce on Allergy Practice Parameters; outside the submitted work. B. J. Lanser reports grants and personal fees from Aimmune Therapeutics; grants from DBV and NIH/NIAID Consortium of Food Allergy Research; and personal fees from Allergenis, and Hycor, outside the submitted work. S. Mustafa reports personal fees from Genentech, AstraZeneca, and Teva; grants and personal fees from Regeneron and CSL Behring; and grants from Shire, outside the submitted work. C. Parrish reports grants and nonfinancial support from DBV Technologies; personal fees from Physician Education Resources, Pharmacy Times Continuing Education; and grants from NIH-NIAID, Novartis, and Regeneron Pharmaceuticals, outside the submitted work. P. Varshney reports grants, personal fees, and nonfinancial support from FARE; grants and nonfinancial support from Aimmune and DBV; personal fees from Dell Children's Medical Center of Central Texas; and nonfinancial support from the American Academy of Allergy, Asthma, and Immunology, outside the submitted work. B. Vlieg-Boerstra reports personal fees from Marfo Food Group (Lelystad, The Netherlands), during the conduct of the study; grants from Nutricia Early Life Nutrition and Nutricia Research; and personal fees from Mead Johnson and Thermofisher, outside the submitted work. S. Sicherer reports personal fees from the American Academy of Allergy, Asthma & Immunology, Johns Hopkins University Press, and UpToDate; grants from HAL Allergy and FARE, outside the submitted work; and reports that he is a medical advisor to I-FPIES. A. Nowak-Wegrzyn reports grants from DBV Technologies, Astellas Pharma, NIH-NIAID, sanofi-aventis, Nutricia Danone, and FARE; grants and personal fees from Nestle and Thermofisher; other fees from UpToDate, Merck, Alk, Regeneron, and Annals of Allergy, Asthma and Immunology; and personal fees from Labcorp, Hycor and Gerber Nutrition Institute, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2019 American Academy of Allergy, Asthma & Immunology
PY - 2020/1
Y1 - 2020/1
N2 - Oral food challenges are an integral part of an allergist's practice and are used to evaluate the presence or absence of allergic reactivity to foods. A work group within the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology was formed to update a previously published oral food challenge report. The intention of this document was to supplement the previous publication with additional focus on safety, treatment of IgE-mediated allergic reactions, guidance for challenges in infants and adults, psychosocial considerations for children and families participating in an oral food challenge, specific guidance for baked milk or baked egg challenges, masking agents and validated blinding recipes for common food allergens, and recommendations for conducting and interpreting challenges in patients with suspected food protein–induced enterocolitis syndrome. Tables and figures within the report and an extensive online appendix detail age-specific portion sizes, appropriate timing for antihistamine discontinuation, serum and skin test result interpretation, written consents, and instructional handouts that may be used in clinical practice.
AB - Oral food challenges are an integral part of an allergist's practice and are used to evaluate the presence or absence of allergic reactivity to foods. A work group within the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology was formed to update a previously published oral food challenge report. The intention of this document was to supplement the previous publication with additional focus on safety, treatment of IgE-mediated allergic reactions, guidance for challenges in infants and adults, psychosocial considerations for children and families participating in an oral food challenge, specific guidance for baked milk or baked egg challenges, masking agents and validated blinding recipes for common food allergens, and recommendations for conducting and interpreting challenges in patients with suspected food protein–induced enterocolitis syndrome. Tables and figures within the report and an extensive online appendix detail age-specific portion sizes, appropriate timing for antihistamine discontinuation, serum and skin test result interpretation, written consents, and instructional handouts that may be used in clinical practice.
KW - Anaphylaxis
KW - Baked egg
KW - Baked milk
KW - Double-blind placebo-controlled food challenge
KW - Egg
KW - FPIES
KW - Food allergy
KW - Food protein–induced enterocolitis syndrome
KW - Milk
KW - Oral food challenge
KW - Peanut
KW - Tree nut
KW - Wheat
UR - http://www.scopus.com/inward/record.url?scp=85077166523&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.09.029
DO - 10.1016/j.jaip.2019.09.029
M3 - Article
C2 - 31950914
AN - SCOPUS:85077166523
SN - 2213-2198
VL - 8
SP - 75-90.e17
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -